Survival and tumor characteristics of German hereditary breast cancer patients
The DOI matches its Crossref record; 41 of the 42 references it cites were found in a registry or an index.
Abstract
Reports from different countries have been inconclusive in attempting to relate the BRCA1 mutation status to the survival of breast cancer patients. The purpose of this study was to investigate overall and disease-free survival for German hereditary breast cancer patients. Data on clinical outcome and data on age at diagnosis of breast cancer, histology, tumor size, lymph node status, histological grade, and laterality of 36 breast cancer patients from 12 families with a BRCA1 mutation and from one family with strong evidence for linkage to BRCA1 were compared with those of 49 hereditary breast cancer patients from 23 families that did not harbor a BRCA1 mutation. Overall and disease-free survival was estimated for both groups. BRCA1 mutation carriers had a significantly earlier age of diagnosis than non-carriers (p = 0.0001) and more frequently developed contralateral breast cancer (p = 0.04). Also, BRCA1-associated tumors more frequently were of larger size (p = 0.041) and higher grade of malignancy (p = 0.005) than non-BRCA1-associated tumors. Whereas no difference in overall survival was seen, disease-free survival at 10 years differed significantly with 53.3% for BRCA1 mutation carriers and 76% for non-carriers (p = 0.02). However, after stratification for age and in multivariate analysis for mutation status, age, and bilaterality, it was shown that the worse prognosis for BRCA1 mutation carriers disappeared. Our results suggest that the worse prognosis of BRCA1 mutation…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297 · cited 1×
“For statistical analysis, mutation carriers were compared to non-carriers using univariate survival analysis using the Kaplan-Meier estimator and multivariate survival analysis using the proportional hazard model [ 27 ].”
MethodA Strong Candidate for the Breast and Ovarian Cancer Susceptibility Gene BRCA1
Miki, Y., Swensen, J., Shattuck-Eidens, D., Futreal, P. A., Harshman, K., Tavtigian, S., Liu, Q., Cochran, C., Bennett, L. M., Ding, W., et al. (1994) · Science · doi:10.1126/science.7545954 · Cited by 6,071 · cited 1×
“In the context of high-risk families, one important gene is the BRCA1 gene on chromosome 17q21 [ 3 ].”
BackgroundGenetic Heterogeneity and Penetrance Analysis of the BRCA1 and BRCA2 Genes in Breast Cancer Families
Ford, D., Easton, D. F., Stratton, M., Narod, S., Goldgar, D., Devilee, P., Bishop, D. T., Weber, B., Lenoir, G., Chang-Claude, J., et al. (1998) · The American Journal of Human Genetics · doi:10.1086/301749 · Cited by 3,037
Self-citationLinkage of Early-Onset Familial Breast Cancer to Chromosome 17q21
Hall, J. M., Lee, M. K., Newman, B., Morrow, J. E., Anderson, L. A., Huey, B., & King, M.-C. (1990) · Science · doi:10.1126/science.2270482 · Cited by 2,550 · cited 1×
“Our study also supported the reported earlier age of diagnosis of women harboring a BRCA1 mutation [ 7 , 9]. Breast cancers in younger patients generally have adverse prognostic factors [29, 30] and were found to have a worse prognosis, especially in patients under 40 years of age [31, 32].”
ResultRisks of cancer in BRCA1-mutation carriers
FORD, D. (1994) · The Lancet · doi:10.1016/s0140-6736(94)91578-4 · Cited by 1,850
Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium.
Easton, D. F., Ford, D., & Bishop, D. T. (1995) · PubMed Central · Cited by 1,602
Burke, W. (1997) · JAMA · doi:10.1001/jama.277.12.997 · Cited by 955
Unusual case of Smith‐Lemli‐Opitz syndrome “type II”
Seller, M. J., Russell, J., & Tint, G. S. (1995) · American Journal of Medical Genetics · doi:10.1002/ajmg.1320560305 · Cited by 585
Stratton, M. R. (1997) · The Lancet · doi:10.1016/s0140-6736(96)10109-4 · Cited by 579
Research works printed but not linked: 1
- Arbeitsgemeinschaft Bevölkerungsbezogener Krebsregister in Deutschland: Krebs in Deutschland. Häufigkeiten und Trends. Arbeitsgemeinschaft Bevölkerungsbezogener Krebsregister in Deutschland (Hrsg), Saarbücken, 1997
Cited by
Germline BRCA1 Mutations and a Basal Epithelial Phenotype in Breast Cancer
Foulkes, W. D. (2003) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/djg050 · Cited by 970
Re: Germline BRCA1 Mutations and a Basal Epithelial Phenotype in Breast Cancer
van der Groep, P., Bouter, A., van der Zanden, R., Menko, F. H., Buerger, H., Verheijen, R. H. M., van der Wall, E., & van Diest, P. J. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh114 · Cited by 798
Robson, M. E., Chappuis, P. O., Satagopan, J., Wong, N., Boyd, J., Goffin, J. R., Hudis, C., Roberge, D., Norton, L., Bégin, L. R., et al. (2003) · Breast Cancer Research · doi:10.1186/bcr658 · Cited by 307
“Several reports suggested that women with germline mutations in BRCA1 are more likely to die from their disease than are women with sporadic breast cancer [3–6].”
BackgroundThe Genetic Epidemiology of Breast Cancer Genes
Thompson, D., & Easton, D. (2004) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1023/b:jomg.0000048770.90334.3b · Cited by 257
Zhong, Q., Peng, H.-L., Zhao, X., Zhang, L., & Hwang, W.-T. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1816 · Cited by 203
“Second, because of the variety of endpoints reported in breast cancer studies, we operationally defined breast cancer PFS to include MFS or DDFS for studies that did not provide DFS and had to exclude LRFS and CRFS results (which were considered to be parts of PFS for some studies) from a few studies.”
Influential
Metadata
- Authors
- Hamann, U., & Sinn, H.-P.
- Affiliations
- German Cancer Research Center (DE)
- Heidelberg University (DE)
- Venue
- Breast Cancer Research and Treatment
- Published
- 2000-01
- Volume
- 59
- Issue
- 2
- Pages
- 185-192
- ISSN
- 0167-6806 (ISSN-L)
- 1573-7217
- OpenAlex
- W2078493457
- Semantic Scholar
- 5dafca3b3ff9d49bd3a1d2cfb00d36ecd01349a6
- Cited by
- 48
- References
- 42
- Citations by year
- 2022: 1 · 2020: 1 · 2019: 1 · 2016: 3 · 2015: 2 · 2014: 2 · 2012: 1
- FWCI
- 3.30
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Breast Cancer Research and Treatment (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
- Health Sciences › Medicine › Pathology and Forensic Medicine › Breast Lesions and Carcinomas
- Health Sciences › Medicine › Epidemiology › Multiple and Secondary Primary Cancers
- Keywords
- hereditary breast cancer, BRCA1 mutation, disease-free survival, overall survival, age at diagnosis, contralateral breast cancer, tumor size, histological grade, prognostic factors, German patients
- MeSH terms
- Adult, Breast Neoplasms, DNA Mutational Analysis, Female, Humans, Middle Aged, Neoplasm Staging, Prognosis, Survival Analysis, Point Mutation, Age of Onset, Genes, BRCA1, Genetic Predisposition to Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Survival and tumor characteristics of German hereditary breast cancer patients. https://app.cochat.ai/papers/10.1023/a:1006350518190
- The paper
- Hamann, U., & Sinn, H.-P. (2000). Survival and tumor characteristics of German hereditary breast cancer patients. Breast Cancer Research and Treatment. https://doi.org/10.1023/a%3A1006350518190
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.